Literature DB >> 27956401

Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.

David Z I Cherney1, Jacob A Udell2.   

Abstract

Keywords:  cardiovascular diseases; diabetes mellitus; heart failure; kidney; prevention and control; sodium-glucose transporter 2

Mesh：

Substances：

Year:  2016        PMID： 27956401     DOI： 10.1161/CIRCULATIONAHA.116.024764

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  14 in total

Review 1.  Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering.

Authors:  Brendon L Neuen; David Z Cherney; Meg J Jardine; Vlado Perkovic
Journal:  CMAJ       Date:  2019-10-15       Impact factor: 8.262

Review 2.  Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.

Authors:  Beatrice C Lupsa; Silvio E Inzucchi
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 3.  Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.

Authors:  Lee-Shing Chang; Muthiah Vaduganathan; Jorge Plutzky; Vanita R Aroda
Journal:  Curr Diab Rep       Date:  2019-12-04       Impact factor: 4.810

Review 4.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

Review 5.  The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

Review 6.  Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.

Authors:  William L Baker; Leo F Buckley; Michael S Kelly; John D Bucheit; Eric D Parod; Roy Brown; Salvatore Carbone; Antonio Abbate; Dave L Dixon
Journal:  J Am Heart Assoc       Date:  2017-05-18       Impact factor: 5.501

7.  Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).

Authors:  Jacob A Udell; Zhong Yuan; Toni Rush; Nicholas M Sicignano; Michael Galitz; Norman Rosenthal
Journal:  Circulation       Date:  2017-11-13       Impact factor: 29.690

8.  Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study.

Authors:  Jacob A Udell; Zhong Yuan; Patrick Ryan; Toni Rush; Nicholas M Sicignano; Michael Galitz; Norman Rosenthal
Journal:  Endocrinol Diabetes Metab       Date:  2019-10-15

Review 9.  Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential.

Authors:  Dulce Brito; Paulo Bettencourt; Davide Carvalho; Jorge Ferreira; Ricardo Fontes-Carvalho; Fátima Franco; Brenda Moura; José Carlos Silva-Cardoso; Rachel Tavares de Melo; Cândida Fonseca
Journal:  Cardiovasc Drugs Ther       Date:  2020-06       Impact factor: 3.947

10.  SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Authors:  Katherine R Tuttle; Frank C Brosius; Matthew A Cavender; Paola Fioretto; Kevin J Fowler; Hiddo J L Heerspink; Tom Manley; Darren K McGuire; Mark E Molitch; Amy K Mottl; Leigh Perreault; Sylvia E Rosas; Peter Rossing; Laura Sola; Volker Vallon; Christoph Wanner; Vlado Perkovic
Journal:  Diabetes       Date:  2020-10-26       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.